RxDoctor Payments Data

John Moore, MD

Internal Medicine · Savannah, GANPI 1255542361

Payments from drug & device makers

$10,469in general payments, 2019–2025

Across 703 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Pfizer$1K
  • AstraZeneca$879
  • Amgen$553
  • Boehringer Ingelheim$409
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$10,469100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,469 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$250,684
Medicare patients
645
Services billed
3,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide210$267,273
EliquisApixaban165$179,288
MounjaroTirzepatide141$157,400
JardianceEmpagliflozin53$71,766
RybelsusSemaglutide34$53,087
XareltoRivaroxaban41$47,494
JanuviaSitagliptin Phosphate31$30,818
LinzessLinaclotide38$30,123
Repatha SureclickEvolocumab37$29,041
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$27,710
MyrbetriqMirabegron19$24,741
Tresiba Flextouch U-200Insulin Degludec31$24,150
FarxigaDapagliflozin Propanediol19$18,634
UbrelvyUbrogepant12$13,705
Tresiba Flextouch U-100Insulin Degludec23$13,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,203$320,361244 claims
PfizerEliquis$1,222$179,288165 claims
Lilly USA, LLCMounjaro, Trulicity$257$167,250152 claims
Boehringer IngelheimJardiance$409$71,76653 claims
AbbVieLinzess, Ubrelvy, Synthroid$1,922$48,225100 claims
Johnson & JohnsonXarelto$118$47,49441 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$274$37,57357 claims
MerckJanuvia$184$30,81831 claims
AstraZenecaFarxiga, Brilinta$879$23,72731 claims
Esperion Therapeutics, Inc.Nexletol$179$5,11711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →